World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
85
Citations
29958
World Ranking
14503
National Ranking
7336

Overview

Vassiliki A. Papadimitrakopoulou is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on the field of Medicine, with a particular concentration on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Pathology and Forensic Medicine, and Surgery.

The main topics addressed in their research include:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Lung Cancer Diagnosis and Treatment
  • Lung Cancer Research Studies
  • Genetic factors in colorectal cancer
  • Colorectal Cancer Treatments and Studies

Among their recent publications are:

  • Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis, 2020, Annals of Oncology
  • Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer, 2021, Journal for ImmunoTherapy of Cancer
  • Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce, 2020, Journal for ImmunoTherapy of Cancer
  • Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02), 2020, Cancer Discovery
  • Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A, 2022, Journal of Clinical Oncology

Their frequent coauthors include John V. Heymach, Roy S. Herbst, Mary W. Redman, David R. Gandara, and Karen Kelly, illustrating collaborative work within the oncology research community.

Vassiliki A. Papadimitrakopoulou has been published frequently in prominent venues including:

  • Journal of Thoracic Oncology
  • Clinical Lung Cancer
  • Journal of Clinical Oncology
  • Journal for ImmunoTherapy of Cancer
  • Nature Communications

Best Publications

  • Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

    Tony S. Mok;Yi Long Wu;Myung Ju Ahn;Marina C. Garassino

  • STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

    Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann

  • Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    Corey J Langer;Shirish M Gadgeel;Hossein Borghaei;Vassiliki A Papadimitrakopoulou

  • The BATTLE Trial: Personalizing Therapy for Lung Cancer

    Edward S. Kim;Roy S. Herbst;Ignacio Ivan Wistuba;Jiun-Kae Jack Lee

  • Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

    Lecia V. Sequist;Jean Charles Soria;Jonathan W. Goldman;Heather A. Wakelee

  • Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

    Ferdinandos Skoulidis;Lauren A. Byers;Lixia Diao;Vassiliki A. Papadimitrakopoulou

  • Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

    Anne O'Donnell;Sandrine Faivre;Howard A. Burris;Daniel Rea

  • Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

    Nathan T. Ihle;Lauren Averett Byers;Edward S. Kim;Pierre Saintigny

  • Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.

    Natasha B. Leighl;Ray D. Page;Victoria M. Raymond;Davey B. Daniel

  • Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development: Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia

    Joyce A. O’Shaughnessy;Gary J. Kelloff;Gary B. Gordon;Andrew J. Dannenberg

  • Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma

    Yanyan Lou;Lixia Diao;Edwin Roger Parra Cuentas;Warren L. Denning

  • CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).

    Yi Long Wu;Myung Ju Ahn;Marina Chiara Garassino;Ji Youn Han

  • Focus on head and neck cancer

    Li Mao;Waun K Hong;Vassiliki A Papadimitrakopoulou

  • CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-l1 blockade

    Limo Chen;Lixia Diao;Yongbin Yang;Xiaohui Yi

  • Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

    Jacqulyne P. Robichaux;Yasir Y. Elamin;Zhi Tan;Brett W. Carter

  • Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.

    Stephen G Swisher;Jack A Roth;Ritsuko Komaki;Jian Gu

  • Scientific Advances in Lung Cancer 2015

    Anne S. Tsao;Giorgio V. Scagliotti;Paul A. Bunn;David P. Carbone

  • Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.

    Xiuning Le;Sonam Puri;Marcelo V. Negrao;Monique B. Nilsson

  • Phase II Randomized, Placebo-Controlled Trial of Green Tea Extract in Patients With High-Risk Oral Premalignant Lesions

    Anne Tsao;Diane Liu;Jack Martin;Xi Ming Tang

  • Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer

    T.S. Mok;Y.-L. Wu;M.-J. Ahn;M.C. Garassino

Frequent Co-Authors

John V. Heymach
John V. Heymach The University of Texas MD Anderson Cancer Center
J. Jack Lee
J. Jack Lee The University of Texas MD Anderson Cancer Center
Roy S. Herbst
Roy S. Herbst Yale University
Ignacio I. Wistuba
Ignacio I. Wistuba The University of Texas MD Anderson Cancer Center
Waun Ki Hong
Waun Ki Hong The University of Texas MD Anderson Cancer Center
George R. Blumenschein
George R. Blumenschein The University of Texas MD Anderson Cancer Center
Bonnie S. Glisson
Bonnie S. Glisson The University of Texas MD Anderson Cancer Center
Scott M. Lippman
Scott M. Lippman University of California, San Diego
Adel K. El-Naggar
Adel K. El-Naggar The University of Texas MD Anderson Cancer Center
David R. Gandara
David R. Gandara University of California, Davis

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine but looking for alternative or complementary education paths, there are numerous online degrees and certifications worth exploring. Many students begin by earning an online bachelor's in health information management, which teaches essential skills in managing medical records and health data—crucial in hospitals and clinics.

Another popular choice is pursuing certifications in billing and coding. Understanding the medical billing and coding certification cost can help you budget for a fast-growing career in healthcare administration.

For those committed to patient care, there are affordable online fnp programs that prepare registered nurses for advanced practice and expanded clinical responsibilities.

Even if you’re just starting, online nursing courses offer flexibility and accreditation, making it easier to begin your nursing journey or upskill while working.

Each of these pathways supports the growing, diverse workforce needed in healthcare today—both in clinical and administrative roles.

Best Scientists Citing Vassiliki A. Papadimitrakopoulou

Trending Scientists